• Chinese
  • English
  • Home
  • Gan & Lee Overview
    • Company Profile
    • Company Culture
    • Marketing Network
    • Member Companies
    • Strategic Partners
    • Gan & Lee History
    • Contact Us
  • Newsroom
    • Media Focus
    • Company News
    • Industry News
    • Honors and Awards
    • International Business
  • Products
    • Insulin Analogue
    • Medical Devices
  • R&D
    • Intellectual Property
  • Social Responsibility
    • Diabetes and Insulin
  • Careers
    • Why choose Gan & Lee
    • What we are looking for
    • What we can offer
    • Join us
  • GDPR POLICY
    • GDPR FOR CHINA
    • GDPR FOR USA
Newsroom
  • Media Focus
  • Company News
  • Industry News
  • Honors and Awards
  • International Business

Fast Track

Company News

  • Home
  • Newsroom
  • Company News
  • 2021-02-22Gan & Lee Announces New Partnership with International Diabetes Federation
  • 2021-02-08Gan & Lee Pharmaceuticals Has Made Significant Commercialization Progress in Brazil
  • 2021-02-01Phase 1 Drug Candidate GLR2007 Developed by Gan & Lee has been Granted Fast Track Designation by the U.S. FDA
  • 2021-01-08Re-acceleration of Global Expansion—Insulin Aspart of Gan & Lee Has Obtained API Registration Certificate in Indonesia
  • 2020-12-22Gan & Lee’s Insulin Glargine Injection Commercialized in Lebanon
  • 2020-11-09BASALIN® (GLARGINE) of GAN & LEE PHARMACEUTICALS WAS APPROVED in KAZAKHSTAN
  • <<
  • 1
  • 2
  • 3
  • 4
  • 5
  • >>

Copyright @ 2016 Gan & Lee Pharmaceuticals. All rights reserved.